News

  • 9 July 2019

    Zogenix enrols last patient in Fintepla’s trial for LGS

    Pharmaceutical firm Zogenix has concluded patient enrolment in a Phase III clinical trial assessing Fintepla (ZX008, fenfluramine) to treat seizures associated with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy.

  • 8 July 2019

    Ipsen-Servier’s Onivyde shows favourable profile in study

    Ipsen and Servier have reported initial findings obtained from an ongoing Phase I/II clinical trial of Onivyde (liposomal irinotecan injection) in previously untreated metastatic pancreatic ductal adenocarcinoma cancer (PDAC) patients.

  • 5 July 2019

    Infant Bacterial enrols first patient in NEC study

    Infant Bacterial Therapeutics (IBT) has started enrolling premature infants in the Phase III Connection clinical trial to evaluate its investigational drug IBP-9414 for the prevention of necrotising enterocolitis (NEC).

Close
Close
Close

Go Top